Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
READY study of relugolix versus dienogest for endometriosis-associated pain
jRCTs061230064Active, not recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in endometriosis comparing Relugolix followed by dienogest with Dienogest (2 arms). Primary endpoint: Change from baseline in maximum VAS score for endometriotic pelvic pain during the primary evaluation period. Started Nov 2023; status: active, not recruiting.
02
Drugs
tissue-plasminogen activatordienogest
03
Conditions
endometriosis
Beyond the preview
Go deeper on jRCTs061230064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061230064.